Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $60.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
